肠促胰素类降糖药物对体重的作用  

Effects of incretin drugs on body weight

作　　者：周欢欢[1] 徐书杭[2] 刘超[2] 楼青青[3] 

机构地区：[1]南京中医药大学护理学院,210023 [2]江苏省中医药研究院,南京中医药大学附属中西医结合医院内分泌代谢病院区,210028 [3]江苏省中医药研究院,南京中医药大学附属中西医结合医院健康教育科,210028

出　　处：《国际内分泌代谢杂志》2016年第3期172-175,共4页International Journal of Endocrinology and Metabolism

摘　　要：胰高血糖素样肽-1（GLP-1）受体激动剂和二肽基肽酶-4（DPP-4）抑制剂是新型的2型糖尿病治疗药物。普遍认为，GLP-1受体激动剂可显著减轻患者体重，DPP-4抑制剂对体重的作用为中性。然而，这两类药物与不同药物联用，患者体重可不同程度增加，尤其是与磺脲类或噻唑烷二酮类药物联用时。临床医师应了解GLP-1受体激动剂和DPP-4抑制剂对体重的影响，为2型糖尿病患者制定更合理、安全和有效的治疗方案。Incretins including glucagon-like peptide-1 （GLP-1） receptor agonists and dipeptidyl peptidase IV （DPP-4） inhibitors are a new type of anti-hyperglycemic drugs. Generally speaking, GLP-1 analogues are associated with significant weight loss, and DPP-4 inhibitors have a neutral effect on body weight. However, they still cause weight gain, particularly when combined with sulfonylureas or thiazolidine- dione. Clinicians should be aware of the influence on body weight of GLP-1 analogues and DPP-4 inhibitors, which can lay the foundation for developing more rational, safe and effective treatments for patients with type 2 diabetes.

关 键 词：2型糖尿病 胰高血糖素样肽-1受体激动剂 二肽基肽酶-4抑制剂 体重 

分 类 号：R587.1[医药卫生—内分泌]